Sep
25
Biopharmaceutical Market & HGH
September 25, 2009 | Leave a Comment
The biopharmaceutical market, estimated to be about $40 billion annually, is one of the fastest-growing segments of the life sciences industry.
When pharmaceutical giants Sandoz (Novartis), launched Omnitrope, its biosimilar version of human growth hormone (HGH) in Germany two years ago, the price was discounted 20% as compared with Eli Lilly’s Humatrope brand. Also, in Australia biosimilar versions of HGH are sold at a 25% discount as compared with their branded counterparts.
Want to know the benefits of an all natural HGH product with no side effects? Click here.
Read the entire biopharmaceutical/HGH article.
Aug
5
Big Booming Biogenerics Company In Competition With Others Who Formulate HGH
August 5, 2009 | Leave a Comment
Israel’s Teva (pronounced teh-vuh) is the world’s biggest generic-drug maker. By making knockoffs faster and in bigger quantities than the competition, the company now accounts for 22% of all generic prescriptions written in the U.S.
Competitors have come out swinging. Swiss drug giant Novartis (NVS) recently won the rights to sell a biogeneric version of Pfizer’s Genotropin, a human growth hormone (HGH), in Japan, and Merck (MRK, Fortune 500) announced plans to develop biogenerics through a division called BioVentures. “Teva is going to be competing with the big boys,” says Sanford Bernstein analyst Ronny Gal.
Want to learn what HGH product is used by tens of thousands? Read what they say by clicking here.
Read the entire biogenerics/HGH article.
Jun
26
Japan Approves First Generic Biotech HGH Drug
June 26, 2009 | Leave a Comment
ZURICH, June 25 (Reuters) - Japanese regulators approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday
Biosimilars are viewed as a promising new market, given the pent-up demand for cheaper versions of extremely expensive biotech drugs, some of which are coming to the end of their patent life.
Somatropin, made by Novartis’ generics unit Sandoz, is for treatment of growth hormone deficiency in children and growth disturbance associated with Turner’s syndrome or chronic renal insufficiency, the group said.
May
13
HGH & Biotechnology
May 13, 2009 | Leave a Comment
(PhysOrg.com) — A new method developed by Cornell biological engineers offers an efficient way to make proteins for use in medicine or industry without the use of live cells. The proteins made in this way include many that cannot be produced by current biotechnology.
Current methods employ vats of genetically modified bacteria or mammalian cells that churn out proteins for such pharmaceuticals as insulin or human growth hormone (hgh). But there are many proteins that bacteria or cells cannot tolerate. Anti-microbials, for example, are meant to kill bacteria and so would kill the host. And many key proteins that are important in regulating the normal life of a cell would also kill the host if overproduced inside a cell.
What other hgh products are available beside the expensive injectible form? Click here to find out!
Mar
11
March 10 (Bloomberg) — Momenta Pharmaceuticals Inc. may become the first drugmaker to win U.S. clearance to sell generic versions of a biotechnology medicine, getting a head start on President Barack Obama’s plan to trim health-care costs by making such copycats commonplace.
Brand-name biotech treatments, which can cost individual consumers or their health plans as much as $200,000 a year, are made from living cells, unlike pharmaceutical medicines that are chemical-based. Generic-drug companies can’t sell copies of brand-name biotechnology drugs because the 1984 U.S. law allowing versions of conventional pills doesn’t provide a system to measure safety and approve so-called biogenerics.
Not all drugs made from living cells are considered by the FDA through the agency’s biologics license application process. For a variety of reasons, some categories of treatments made using living cells, including insulin, human growth hormone (hgh) and heparins, were approved under the process for conventional medications.
Read the entire Bloomberg,HGH article
Oct
23
HGH Biosimiliars In The News
October 23, 2008 | Leave a Comment
A surge in research into novel drug delivery systems will occur as companies seek to differentiate their products in response to pressure from biosimilars, according to a publication from Frost & Sullivan.
The European Medicine Agency’s (EMEA) approval of Sandoz’s biosimilar human growth hormone (HGH), Omnitrope, in 2006, has cut the cost of treatment by 25 per cent. In response to this, Frost & Sullivan recommends that companies should seek to invest in drug delivery technologies to differentiate their products.
Oct
6
Investing In HGH: Big Business
October 6, 2008 | Leave a Comment
Human growth hormone (hgh; somatropin) was the first therapeutic protein for which a biosimilar version was approved in the US and in Europe in 2006.
There are numerous manufacturers of human growth hormone (hgh)Â in non-regulated markets, but most of them do not produce in a manner allowing approval in regulated markets although these products are frequently consumed by those interested in gaining muscle mass. Manufacturers in non-regulated markets are also investing in development of next generation human growth hormone (hgh)Â products and some of them invest in WHO-GMP compliant infrastructure.
Read about the top selling hgh product available today, no prescription needed! Click here!
Sep
15
HGH Treating Blood Disorder
September 15, 2008 | Leave a Comment
A new form of human growth hormone (hgh)Â is being used to treat a rare blood disorder:
Teva Pharmaceutical Industries Ltd. yesterday obtained marketing authorization from the European Commission Directorate General for Enterprise and Industry for TevaGrastim, a human granulocyte colony stimulating factor (G-CSF) product. It is a biosimilar product of Neupogen Filgrastim, a recombinant DNA treatment for chemotherapy-induced neutropenia (a blood disorder) made by Amgen Inc.
Read more about the benefits of HGH and the top selling HGH product on the market today! Click here.
Read the entire hgh/blood disorder article by clicking here.
Jul
10
Biopharmaceutical HGH Company In The News
July 10, 2008 | Leave a Comment
Manufacturing of biopharmaceuticals is in the news once again:
The consolidation process in the biogenerics industry has commenced after first approvals of biogeneric human growth hormone (hgh)Â products in the US and the EU and first filings of biogeneric erythropoietin and insulin in the EU. Smaller biogeneric companies have been taken over by generic players from India and Eastern Europe.
Read what a doctor has to say about hgh.
May
29
 Biosimilair versions of HGH recently received approval in Europe.
LONDON - With the first generic biologics reaching the market in Europe, the focus has shifted from arguments about how to approve them, to how the products should be used in clinical practice.
Rather than biogenerics, the European Medicines Agency (EMEA) has tagged the products as biosimilars. The explicit recognition that they are not exactly the same as the originator product is raising issues of substitutability and pharmacovigilance.
Two biosimilar versions of erythropoietin (EPO) and two of somatrophin (human growth hormone) have been approved, a G-CSF biogeneric is about to get the nod and there will be many more products on the market in the next five years, making it essential that processes are in place to ensure their safe and appropriate use.
Recommended Links
GET YOUR FREE HGH &
ANTI-AGING REPORT!
- Get your own FREE copy of the groundbreaking report, "Seven Age Reversing Secrets" – packed with valuable tips and tricks to help you fight the aging process and have the highest quality of life possible!